NO20022334L - Ny sammensetning og anvendelse - Google Patents

Ny sammensetning og anvendelse

Info

Publication number
NO20022334L
NO20022334L NO20022334A NO20022334A NO20022334L NO 20022334 L NO20022334 L NO 20022334L NO 20022334 A NO20022334 A NO 20022334A NO 20022334 A NO20022334 A NO 20022334A NO 20022334 L NO20022334 L NO 20022334L
Authority
NO
Norway
Prior art keywords
application
new composition
composition
new
Prior art date
Application number
NO20022334A
Other languages
English (en)
Other versions
NO329926B1 (no
NO20022334D0 (no
Inventor
Nicola Jayne Lilliott
Donald Colin Mackenzie
Karen Lewis
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27447849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20022334(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9927119.9A external-priority patent/GB9927119D0/en
Priority claimed from GBGB9927120.7A external-priority patent/GB9927120D0/en
Priority claimed from GB0013236A external-priority patent/GB0013236D0/en
Priority claimed from GB0013240A external-priority patent/GB0013240D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20022334D0 publication Critical patent/NO20022334D0/no
Publication of NO20022334L publication Critical patent/NO20022334L/no
Publication of NO329926B1 publication Critical patent/NO329926B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20022334A 1999-11-16 2002-05-15 Farmasoytisk sammensetning og fremgangsmate for fremstilling derav NO329926B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9927119.9A GB9927119D0 (en) 1999-11-16 1999-11-16 Novel composition and use
GBGB9927120.7A GB9927120D0 (en) 1999-11-16 1999-11-16 Novel composition and use
GB0013236A GB0013236D0 (en) 2000-05-31 2000-05-31 Novel composition and use
GB0013240A GB0013240D0 (en) 2000-05-31 2000-05-31 Novel composition and use
PCT/GB2000/004368 WO2001035941A2 (en) 1999-11-16 2000-11-16 Novel composition based on a thiazolidinedione and metformin and use

Publications (3)

Publication Number Publication Date
NO20022334D0 NO20022334D0 (no) 2002-05-15
NO20022334L true NO20022334L (no) 2002-07-09
NO329926B1 NO329926B1 (no) 2011-01-24

Family

ID=27447849

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022334A NO329926B1 (no) 1999-11-16 2002-05-15 Farmasoytisk sammensetning og fremgangsmate for fremstilling derav

Country Status (40)

Country Link
US (1) US8236345B2 (no)
EP (3) EP1231918B1 (no)
JP (2) JP4865975B2 (no)
KR (1) KR100760063B1 (no)
CN (1) CN1222290C (no)
AP (1) AP1389A (no)
AR (2) AR030920A1 (no)
AT (1) ATE292466T1 (no)
AU (3) AU775654B2 (no)
BG (1) BG65616B1 (no)
BR (1) BR0015605A (no)
CA (1) CA2388846A1 (no)
CO (1) CO5300392A1 (no)
CZ (1) CZ302500B6 (no)
DE (1) DE60019329T2 (no)
DK (1) DK1231918T3 (no)
DZ (1) DZ3251A1 (no)
EA (1) EA004878B1 (no)
ES (1) ES2240199T3 (no)
HK (1) HK1049788B (no)
HR (1) HRP20020416B1 (no)
HU (1) HU229960B1 (no)
IL (3) IL149618A0 (no)
MA (1) MA25567A1 (no)
ME (1) ME00318B (no)
MX (1) MXPA02005005A (no)
MY (1) MY125516A (no)
NO (1) NO329926B1 (no)
NZ (1) NZ518946A (no)
OA (1) OA12513A (no)
PE (1) PE20011011A1 (no)
PL (1) PL200943B1 (no)
PT (1) PT1231918E (no)
RS (1) RS51343B (no)
SI (1) SI1231918T1 (no)
SK (1) SK286985B6 (no)
TW (1) TWI240626B (no)
UA (1) UA73150C2 (no)
UY (1) UY26439A1 (no)
WO (1) WO2001035941A2 (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407713A1 (en) * 2000-05-01 2001-11-08 Aeropharm Technology, Inc. A core formulation
CA2453782A1 (en) * 2001-07-10 2003-01-23 Kos Life Sciences, Inc. Core formulation comprising troglitazone and a biguanide
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
AU2002356419A1 (en) * 2002-06-17 2003-12-31 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
WO2004006921A1 (ja) * 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited 被覆製剤の製造法
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2004026241A2 (en) * 2002-09-20 2004-04-01 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
NZ541749A (en) 2003-01-29 2009-06-26 Takeda Pharmaceutical Process for producing coated preparation comprising pioglitazone hydrochloride and a coating material
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
CA2562391A1 (en) * 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
JPWO2006011397A1 (ja) * 2004-07-27 2008-05-01 興和株式会社 糖尿病の予防または治療のための薬剤
PL1878426T3 (pl) * 2005-04-26 2010-11-30 Sumitomo Dainippon Pharma Co Ltd Preparat w formie granulatu zawierający związek biguanidu
AR058605A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Preparacion solida
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
WO2008078390A1 (ja) 2006-12-26 2008-07-03 Fujitsu Limited データ圧縮装置およびデータ復元装置
MY147596A (en) 2007-02-01 2012-12-31 Takeda Pharmaceutical Solid preparation comprising alogliptin and pioglitazone
JP5467870B2 (ja) 2007-02-09 2014-04-09 アルファファーム ピーティーワイ リミテッド 異なる物理的形態の２種以上の有効医薬成分を含有する投薬形態
TR200803177A2 (tr) * 2008-05-06 2009-11-23 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Antihiperglisemik etkili metformîn - pioglitazon formülasyonu.
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
SI2324126T1 (sl) 2008-08-12 2014-07-31 Zinfandel Pharmaceuticals, Inc. Postopek identifikacije dejavnikov tveganja za Alzheimerjevo bolezen
FR2951945B1 (fr) * 2009-11-05 2013-08-09 Sanofi Aventis Composition pharmaceutique
PL2498758T3 (pl) * 2009-11-13 2019-02-28 Astrazeneca Ab Formulacje tabletek dwuwarstwowych
EP2441442A1 (en) 2010-10-08 2012-04-18 LEK Pharmaceuticals d.d. A pharmaceutical composition comprising a thiazolidinedione
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
EP3763419A1 (en) 2011-01-07 2021-01-13 Anji Pharma (US) LLC Chemosensory receptor ligand-based therapies
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
GEP201706786B (en) 2011-01-10 2017-12-11 Takeda Pharmaceuticals Co Methods and drug products for treating alzheimer's disease
JP2015503582A (ja) 2012-01-06 2015-02-02 エルセリクス セラピューティクス インコーポレイテッド ビグアナイド組成物および代謝障害を治療する方法
NZ626578A (en) 2012-01-06 2016-11-25 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
CN108451923A (zh) * 2018-05-31 2018-08-28 常州兰陵制药有限公司 盐酸二甲双胍速释胶囊及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4613596Y1 (no) * 1969-06-02 1971-05-14
DE2347531A1 (de) * 1973-09-21 1975-04-30 Hoechst Ag Arzneizubereitungen zur oralen diabetes-behandlung
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
JPH0553521A (ja) 1991-08-28 1993-03-05 Mitsubishi Electric Corp オートトラツキング型ｃｒｔデイスプレイモニタ
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US6183778B1 (en) * 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
GB2350319B (en) 1996-06-14 2001-01-10 Rue De Int Ltd Security printed device
PE71699A1 (es) 1997-02-07 1999-08-03 Sepracor Inc Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
ES2284212T3 (es) * 1997-06-18 2007-11-01 Smithkline Beecham Plc Tratamiento de diabetes con tiazolidinadiona y metformina.
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6117451A (en) * 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
EP1813273A1 (en) 1998-11-12 2007-08-01 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
GB9824893D0 (en) 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
AR023699A1 (es) 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
AU1403501A (en) 1999-11-16 2001-05-30 Smithkline Beecham Plc Novel composition and use
US6780432B1 (en) * 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
US6403121B1 (en) * 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
US6524621B2 (en) * 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6461639B2 (en) * 2000-05-01 2002-10-08 Aeropharm Technology, Inc. Core formulation
US6296874B1 (en) * 2000-05-01 2001-10-02 Aeropharm Technology Incorporated Core formulation comprising troglitazone and abiguanide
US6451342B2 (en) * 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition

Also Published As

Publication number Publication date
PE20011011A1 (es) 2001-10-28
OA12513A (en) 2006-05-29
AR030920A1 (es) 2003-09-03
KR100760063B1 (ko) 2007-09-18
PL200943B1 (pl) 2009-02-27
DE60019329T2 (de) 2006-03-09
JP5282130B2 (ja) 2013-09-04
AU1404001A (en) 2001-05-30
TWI240626B (en) 2005-10-01
DE60019329D1 (de) 2005-05-12
AP2002002505A0 (en) 2002-06-30
DK1231918T3 (da) 2005-08-01
WO2001035941A2 (en) 2001-05-25
AU2004226955B2 (en) 2008-08-28
US8236345B2 (en) 2012-08-07
DZ3251A1 (fr) 2001-05-25
ATE292466T1 (de) 2005-04-15
BG106747A (en) 2003-01-31
WO2001035941A3 (en) 2002-05-23
SI1231918T1 (en) 2005-08-31
CA2388846A1 (en) 2001-05-25
CN1414852A (zh) 2003-04-30
HK1049788A1 (en) 2003-05-30
MY125516A (en) 2006-08-30
CN1222290C (zh) 2005-10-12
AU2008207375A1 (en) 2008-09-11
BR0015605A (pt) 2002-07-09
AU2004226955A1 (en) 2004-12-02
WO2001035941A8 (en) 2002-08-29
RS51343B (sr) 2011-02-28
AR057970A2 (es) 2007-12-26
HK1049788B (zh) 2005-11-04
EA200200571A1 (ru) 2002-12-26
IL149618A0 (en) 2002-12-01
MXPA02005005A (es) 2003-10-14
ME00318B (me) 2011-05-10
NZ518946A (en) 2003-10-31
EP1913945A3 (en) 2008-04-30
SK286985B6 (sk) 2009-08-06
HRP20020416A2 (en) 2004-08-31
HUP0204122A2 (hu) 2003-03-28
KR20030019300A (ko) 2003-03-06
JP4865975B2 (ja) 2012-02-01
JP2011252007A (ja) 2011-12-15
PL355331A1 (en) 2004-04-19
UA73150C2 (uk) 2005-06-15
YU38802A (sh) 2005-03-15
SK6792002A3 (en) 2002-09-10
NO329926B1 (no) 2011-01-24
EP1231918A2 (en) 2002-08-21
AU775654B2 (en) 2004-08-12
BG65616B1 (bg) 2009-03-31
MEP34008A (en) 2011-02-10
EP1231918B1 (en) 2005-04-06
ES2240199T3 (es) 2005-10-16
CZ302500B6 (cs) 2011-06-22
JP2003514012A (ja) 2003-04-15
NO20022334D0 (no) 2002-05-15
US20070275054A1 (en) 2007-11-29
HU229960B1 (hu) 2015-03-30
EP1913945A2 (en) 2008-04-23
AP1389A (en) 2005-04-14
CO5300392A1 (es) 2003-07-31
HRP20020416B1 (en) 2011-04-30
IL190220A0 (en) 2008-11-03
IL149618A (en) 2008-07-08
UY26439A1 (es) 2001-07-31
MA25567A1 (fr) 2002-10-01
PT1231918E (pt) 2005-08-31
HUP0204122A3 (en) 2006-01-30
EP1520581A1 (en) 2005-04-06
EA004878B1 (ru) 2004-08-26

Similar Documents

Publication Publication Date Title
NO20022334L (no) Ny sammensetning og anvendelse
DK1233964T3 (da) Ny anvendelse og hidtil ukendte N-azabicycloamidderivater
NO20032753D0 (no) Forbindelse og anvendelse derav
NO20013393L (no) Bronnsementeringsfremgangsmater og sammensetninger
NO20006488D0 (no) Sammensetning og anvendelse
NO20021116D0 (no) Ny sammensetning
DK1112003T3 (da) Ny sammensætning og anvendelse
NO20000847D0 (no) Elastiske brønnsementsammensetninger og fremgangsmåter
NO20000011D0 (no) Skumdempersammensetninger og fremgangsmåter
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
IS6411A (is) Kaspasa tálmar og notkun þeirra
DE50112013D1 (de) Deodorantien und antiperspirantien
DK1339292T3 (da) Sammensætning og fremgangsmåde
NO20021115L (no) Ny sammensetning
PT1139761E (pt) Composicoes herbicidas e concentrados tensioactivos
DE69916503D1 (de) Poliermittelzusammensetzung und anwendungsverfahren
DE69916694D1 (de) 2-Hydroxy-5-methyl-hexan-3-on und 3-hydroxy-5-methyl-hexan-2-on
DE60028486D1 (de) Videocoder und -decoder
DE60032898D1 (de) Arylthiazolidindion- und aryloxazolidinderivate
NO20005763L (no) DHEA-sammensetning og fremgangsmåte
FIU990494U0 (fi) Uusi koostumus
NO20013085D0 (no) Fosfororganiske forbindelser og deres anvendelse
NO20006626D0 (no) Beleggingsmiddel og anvendelse herav
NO20005483D0 (no) Ny sammensetning
NO20011313L (no) Ny sammensetning

Legal Events

Date Code Title Description
MK1K Patent expired